Literature DB >> 15987229

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease.

Kristen Migliaccio-Walle1, J Jaime Caro, Khajak J Ishak, Judith A O'Brien.   

Abstract

BACKGROUND: Peripheral arterial disease (PAD) is increasingly recognised as an indicator of disseminated atherothrombosis, but its impact on use of healthcare resources is not well understood.
OBJECTIVE: To provide a quantitative description of the resource utilisation and costs incurred following PAD.
METHODS: Hospitalisations, physician visits and the corresponding direct medical costs were examined in 16,440 patients with a diagnosis of PAD (1985--1995) in Saskatchewan, Canada, and compared with 15,590 reference patients with a diagnosis of myocardial infarction (MI) [1990--1995]. Medical history and patient characteristics were available retrospectively to January 1980 and follow-up to December 2000. Rates and timing of all-cause and cardiovascular hospitalisations and physician visits within discrete periods in the 10 years following PAD diagnosis, and 5 years following MI, were evaluated, as were lengths of stay and predictors of hospitalisation.
RESULTS: Average follow-up was 5.9 years among patients with PAD and 3.6 years for MI. Half (55%) of patients with PAD were male versus 64% of reference patients. The mean ages were 67.3 and 66.9 years, respectively. Patients with PAD were hospitalised most frequently soon after diagnosis, with rates subsequently decreasing to 0.14 per month. These rates were similar in the reference group except for the period immediately following MI. The average 5-year cost post-diagnosis (2002 Can dollars) per patient was 41,968 Can dollars vs 48,578 Can dollars for the reference population.
CONCLUSIONS: A diagnosis of PAD not only imposes a severe burden on patients and their families, but it also significantly increases the use of healthcare resources and the associated costs. By the end of year 1, this burden is comparable with a diagnosis of MI.

Entities:  

Mesh:

Year:  2005        PMID: 15987229     DOI: 10.2165/00019053-200523070-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  19 in total

1.  Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease.

Authors:  A Stergachis; S Sheingold; B R Luce; B M Psaty; D A Revicki
Journal:  Arch Intern Med       Date:  1992-06

2.  Mortality over a period of 10 years in patients with peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

Review 3.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review.

Authors:  J I Weitz; J Byrne; G P Clagett; M E Farkouh; J M Porter; D L Sackett; D E Strandness; L M Taylor
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

4.  Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events.

Authors:  J J Caro; K Migliaccio-Walle
Journal:  Am J Med       Date:  1999-12       Impact factor: 4.965

5.  Low rates of preventive practices in patients with peripheral vascular disease.

Authors:  S S Anand; A Kundi; J Eikelboom; S Yusuf
Journal:  Can J Cardiol       Date:  1999-11       Impact factor: 5.223

6.  Intermittent claudication in 8343 men and 21-year specific mortality follow-up.

Authors:  S J Bowlin; J H Medalie; S A Flocke; S J Zyzanski; S Yaari; U Goldbourt
Journal:  Ann Epidemiol       Date:  1997-04       Impact factor: 3.797

7.  Intermittent claudication. A risk profile from The Framingham Heart Study.

Authors:  J M Murabito; R B D'Agostino; H Silbershatz; W F Wilson
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

Review 8.  Peripheral arterial disease--epidemiological aspects.

Authors:  M H Criqui
Journal:  Vasc Med       Date:  2001       Impact factor: 3.239

9.  Peripheral arterial disease detection, awareness, and treatment in primary care.

Authors:  A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

10.  Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study.

Authors:  M A Howell; M P Colgan; R W Seeger; D E Ramsey; D S Sumner
Journal:  J Vasc Surg       Date:  1989-05       Impact factor: 4.268

View more
  5 in total

1.  The economic burden of atherothrombosis in Greece: results from the THESIS study.

Authors:  Nikos Maniadakis; Georgia Kourlaba; Dennis V Cokkinos; Aggeliki Angeli; John Kyriopoulos
Journal:  Eur J Health Econ       Date:  2012-07-10

Review 2.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

Review 3.  Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology.

Authors:  Joshua W Knowles; Themistocles L Assimes; Jun Li; Thomas Quertermous; John P Cooke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-26       Impact factor: 8.311

4.  The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada.

Authors:  J Jaime Caro; Kristen Migliaccio-Walle; Khajak J Ishak; Irina Proskorovsky; Judith A O'Brien
Journal:  BMC Health Serv Res       Date:  2006-08-14       Impact factor: 2.655

5.  The ratchet effect: dramatic and sustained changes in health care utilization following admission to hospital with chronic disease.

Authors:  David Whyatt; Raji Tenneti; Julie Marsh; Sarah E Bolt; Anna Kemp; Laura Firth; Kevin Murray; Berwin Turlach; Alistair Vickery
Journal:  Med Care       Date:  2014-10       Impact factor: 2.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.